Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women with Osteoporosis and Varying Baseline Risk Factors

Introduction: Abaloparatide-SC is an investigational, novel, selective activator of the parathyroid hormone type 1 receptor signaling pathway. In the global, phase 3 ACTIVE (Abaloparatide Comparator Trial in Vertebral Endpoints) trial of 2463 postmenopausal women with osteoporosis, abaloparatide-SC significantly reduced the risk of vertebral and nonvertebral fractures compared to placebo, and significantly reduced the risk of major osteoporotic fractures compared to teriparatide. Abaloparatide-SC also significantly increased bone mineral density (BMD) at the total hip, femoral neck, and lumbar spine at 18 months compared to placebo.
Source: Journal of Clinical Densitometry - Category: Radiology Authors: Source Type: research